Agomelatine beyond borders: Current evidences of its efficacy in disorders other than major depression

International Journal of Molecular Sciences

Volumn 16, Issue 1, 2015, Pages 1111-1130

  De Berardis, Domenico ^a,b   Fornaro, Michele ^c   Serroni, Nicola ^b   Campanella, Daniela ^b   Rapini, Gabriella ^b   Olivieri, Luigi ^a   Srinivasan, Venkataramanujam ^d   Iasevoli, Felice ^e   Tomasetti, Carmine ^e   De Bartolomeis, Andrea ^e   Valchera, Alessandro ^f   Perna, Giampaolo ^g,h,i   Mazza, Monica ^j   Nicola, Marco Di ^k   Martinotti, Giovanni ^b   Giannantonio, Massimo Di ^b  

^a National Health Service Department of Mental Health Psychiatric Service of Diagnosis and Treatment Hospital G Mazzini   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d Sri Sathya Sai Medical Educational and Research Foundation   (India)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f Hermanas Hospitalarias   (Italy)

^g Hermanas Hospitalarias FoRiPsi Department of Clinical Neurosciences Villa San Benedetto Menni ^*  (Italy)

^h UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

ⁱ MAASTRICHT UNIVERSITY   (Netherlands)

^j UNIVERSITY OF L'AQUILA   (Italy)

^k CATHOLIC UNIVERSITY   (Italy)

more..

Author keywords

Agomelatine; Alcohol dependence; Anxiety; Bipolar depression; Dopamine; Fibromyalgia; Melatonergic receptors; Melatonin; Migraines; Noradrenaline; Psychiatric disorders; Schizophrenia; Seasonal affective disorder; Serotonin

Indexed keywords

AGOMELATINE; ACETAMIDE DERIVATIVE; ANTIDEPRESSANT AGENT; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; SEROTONIN 2C RECEPTOR;

ALCOHOLISM; BIPOLAR DEPRESSION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FIBROMYALGIA; GENERALIZED ANXIETY DISORDER; HEADACHE; HUMAN; INSOMNIA; MAJOR DEPRESSION; META ANALYSIS (TOPIC); MIGRAINE; MULTICENTER STUDY (TOPIC); NAUSEA; NONHUMAN; PANIC; PARTIAL RESPONDER SCHIZOPHRENIA; POSTTRAUMATIC STRESS DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHIZOPHRENIA; SEASONAL AFFECTIVE DISORDER; SEDATION; SLEEP DISORDER; SOCIAL PHOBIA; SOMNOLENCE; TRANQUILIZING ACTIVITY; BIPOLAR DISORDER; CHEMISTRY; DEPRESSIVE DISORDER; METABOLISM; MIGRAINE DISORDERS; SLEEP WAKE DISORDERS;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER; FIBROMYALGIA; HUMANS; MIGRAINE DISORDERS; RECEPTOR, MELATONIN, MT1; RECEPTOR, MELATONIN, MT2; RECEPTOR, SEROTONIN, 5-HT2C; SCHIZOPHRENIA; SLEEP WAKE DISORDERS;

EID: 84920516887     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms16011111     Document Type: Review

References (100)

1. Srinivasan, V.; de Berardis, D.; Shillcutt, S.D.; Brzezinski, A. Role of melatonin in mood disorders and the antidepressant effects of agomelatine. Expert Opin. Investig. Drugs 2012, 21, 1503–1522.
2. De Berardis, D.; Marini, S.; Fornaro, M.; Srinivasan, V.; Iasevoli, F.; Tomasetti, C.; Valchera, A.; Perna, G.; Quera-Salva, M.A.; Martinotti, G. et al. The melatonergic system in mood and anxiety disorders and the role of agomelatine: Implications for clinical practice. Int. J. Mol. Sci. 2013, 14, 12458–12458.
3. Barden, N.; Shink, E.; Labbé, M.; Vacher, R.; Rochford, J.; Mocaër, E. Antidepressant action of agomelatine (S 20098) in a transgenic mouse model. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29, 908–916.
4. MacIsaac, S.E.; Carvalho, A.F.; Cha, D.S.; Mansur, R.B.; McIntyre, R.S. The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin. Pharmacother. 2014, 15, 259–274.
5. Masana, M.I.; Benloucif, S.; Dubocovich, M.L. Circadian rhythm of mt1 melatonin receptor expression in the suprachiasmatic nucleus of the C3H/HeN mouse. J. Pineal Res. 2000, 28, 185–192.
6. Brown, T.M.; Piggins, H.D. Electrophysiology of the suprachiasmatic circadian clock. Prog. Neurobiol. 2007, 82, 229–255.
7. Leproult, R.; van Onderbergen, A.; L’hermite-Balériaux, M.; van Cauter, E.; Copinschi, G. Phase-shifts of 24 h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men. Clin. Endocrinol. 2005, 63, 298–304.
8. Tardito, D.; Molteni, R.; Popoli, M.; Racagni, G. Synergistic mechanisms involved in the antidepressant effects of agomelatine. Eur. Neuropsychopharmacol. 2012, 22, 482–486.
9. Bertaina-Anglade, V.; Drieu-La-Rochelle, C.; Mocaër, E.; Seguin, L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol. Biochem. Behav. 2011, 98, 511–517.
10. San, L.; Arranz, B. Agomelatine: A novel mechanism of antidepressant action involving the melatonergic and the serotonergic system. Eur. Psychiatry 2008, 23, 396–402.
11. Fornaro, M.; Prestia, D.; Colicchio, S.; Perugi, G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr. Neuropharmacol. 2010, 8, 287–304.
12. Fornaro, M.; Bandini, F.; Cestari, L.; Cordano, C.; Ogliastro, C.; Albano, C.; de Berardis, D.; Martino, M.; Escelsior, A.; Rocchi G. et al. Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug? Neuropsychiatr. Dis. Treat. 2014, 10, 907–914.
13. De Berardis, D.; di Iorio, G.; Acciavatti, T.; Conti, C.; Serroni, N.; Olivieri, L.; Cavuto, M.; Martinotti, G.; Janiri, L.; Moschetta, F.S. et al. The emerging role of melatonin agonists in the treatment of major depression: Focus on agomelatine. CNS Neurol. Disord. Drug Targets 2011, 10, 119–132.
14. Di Giannantonio, M.; Martinotti, G. Anhedonia and major depression: The role of agomelatine. Eur. Neuropsychopharmacol. 2012, 22, 505–510.
15. Pompili, M.; Serafini, G.; Innamorati, M.; Venturini, P.; Fusar-Poli, P.; Sher, L.; Amore, M.; Girardi, P. Agomelatine, a novel intriguing antidepressant option enhancing neuroplasticity: A critical review. World J. Biol. Psychiatry 2013, 14, 412–431.
16. Di Giannantonio, M.; di Iorio, G.; Guglielmo, R.; de Berardis, D.; Conti, C.M.; Acciavatti, T.; Cornelio, M.; Martinotti, G. Major depressive disorder, anhedonia and agomelatine: An open-label study. J. Biol. Regul. Homeost. Agents 2011, 25, 109–114.
17. De Berardis, D.; Brucchi, M.; Serroni, N.; Valchera, A.; Fornaro, M.; Mazza, M.; Martinotti, G.; di Giannantonio, M. Successful use of agomelatine in the treatment of major depression in a woman taking tamoxifen: A case report. Clin. Neuropharmacol. 2014, 37, 31–33.
18. Di Nicola, M.; de Risio, L.; Battaglia, C.; Camardese, G.; Tedeschi, D.; Mazza, M.; Martinotti, G.; Pozzi, G.; Niolu, C.; di Giannantonio, M. et al. Reduced hedonic capacity in euthymic bipolar subjects: A trait-like feature? J. Affect. Disord. 2013, 147, 446–450.
19. Hatzigiakoumis, D.S.; Martinotti, G.; di Giannantonio, M.; Janiri, L. Anhedonia and substance dependence: Clinical correlates and treatment options. Front. Psychiatry 2011, 17, 10.
20. De Berardis, D.; Fornaro, M.; Serroni, N.; Olivieri, L.; Marini, S.; Moschetta, F.S.; Srinivasan, V.; Assetta, M.; Valchera, A.; Salone, A. et al. Agomelatine treatment of major depressive disorder in Parkinson’s disease: A case series. J. Neuropsychiatry Clin. Neurosci. 2013, 25, 343–345.
21. Ladurelle, N.; Gabriel, C.; Viggiano, A.; Mocaër, E.; Baulieu, E.E.; Bianchi, M. Agomelatine (S20098) modulates the expression of cytoskeletal microtubular proteins, synaptic markers and BDNF in the rat hippocampus, amygdala and PFC. Psychopharmacology 2012, 221, 493–509.
22. Martinotti, G.; Sepede, G.; Gambi, F.; di Iorio, G.; de Berardis, D.; di Nicola, M.; Onofrj, M.; Janiri, L.; di Giannantonio, M. Agomelatine vs venlafaxine XR in the treatment of anhedonia in major depressive disorder: A pilot study. J. Clin. Psychopharmacol. 2012, 32, 487–491.
23. Kennedy, S.H.; Avedisova, A.; Giménez-Montesinos, N.; Belaïdi, C.; de Bodinat, C.; Agomelatine Study Group. A placebo-controlled study of three agomelatine dose regimens (10 mg, 25 mg, 25–50 mg) in patients with major depressive disorder. Eur. Neuropsychopharmacol. 2014, 24, 553–563.
24. Hale, A.; Corral, R.M.; Mencacci, C.; Ruiz, J.S.; Severo, C.A.; Gentil, V. Superior antidepressant efficacy results of agomelatine vs. fluoxetine in severe MDD patients: A randomized, double-blind study. Int. Clin. Psychopharmacol. 2010, 25, 305–314.
25. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.J.; Montejo, A.L.; Smeraldi, E.; Rybakowski, J.K.; Quera-Salva, M.A.; Wirz-Justice, A.M.; Picarel-Blanchot, F. et al. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, double-blind comparison with sertraline. J. Clin. Psychiatr. 2010, 71, 109–120.
26. Corruble, E.; de Bodinat, C.; Belaïdi, C.; Goodwin, G.M. agomelatine study group. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: A 24-wk randomized, controlled, double-blind trial. Int. J. Neuropsychopharmacol. 2013, 16, 2219–2234.
27. Huang, K.L.; Lu, W.C.; Wang, Y.Y.; Hu, G.C.; Lu, C.H.; Lee, W.Y.; Hsu, C.C. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. Aust. N. Z. J. Psychiatry 2014, 48, 663–671.
28. Heun, R.; Ahokas, A.; Boyer, P.; Giménez-Montesinos, N.; Pontes-Soares, F.; Olivier, V.; Agomelatine Study Group. The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: A placebo-controlled study. J. Clin. Psychiatry 2013, 74, 587–594.
29. European Medicines Agency. CHMP Assessment Report for Valdoxan. Document Reference EMEA/655251/2008; European Medicines Agency: London, UK, 2008.
30. Taylor, D.; Sparshatt, A.; Varma, S.; Olofinjana, O. Antidepressant efficacy of agomelatine: Meta-analysis of published and unpublished studies. BMJ 2014, 348, g1888.
31. Koesters, M.; Guaiana, G.; Cipriani, A.; Becker, T.; Barbui, C. Agomelatine efficacy and acceptability revisited: Systematic review and meta-analysis of published and unpublished randomised trials. Br. J. Psychiatry 2013, 203, 179–187.
32. Guaiana, G.; Gupta, S.; Chiodo, D.; Davies, S.J.; Haederle, K.; Koesters, M. Agomelatine vs. other antidepressive agents for major depression. Cochrane Database Syst. Rev. 2013, 12, CD008851.
33. Montejo, A.; Prieto, N.; Terleira, A.; Matias, J.; Alonso, S.; Paniagua, G.; Naval, S.; Parra, D.G.; Gabriel, C.; Mocaër, E. et al. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers: An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol. 2010, 24, 111–120.
34. Montgomery, S.A.; Kennedy, S.H.; Burrows, G.D.; Lejoyeux, M.; Hindmarch, I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int. Clin. Psychopharmacol. 2004, 19, 271–280.
35. Howland, R.H. A benefit-risk assessment of agomelatine in the treatment of major depression. Drug Saf. 2011, 34, 709–731.
36. Servier Laboratories Ltd. Valdoxan (Agomelatine) Summary of Product Characteristics, 2009. Available online: http://emc.medicines.org.uk/medicine/21830/SPC/Valdoxan/ (accessed on 25 July 2014).
37. Buoli, M.; Mauri, M.C.; Altamura, A.C. Pharmacokinetic evaluation of agomelatine for the treatment of generalised anxiety disorder. Expert Opin. Drug Metab. Toxicol. 2014, 10, 885–892.
38. Benedetti, F. Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin. Neurosci. 2012, 14, 401–411.
39. Fornaro, M.; de Berardis, D.; Iasevoli, F.; Pistorio, M.L.; D’Angelo, E.; Mungo, S.; Martino, M.; Ventriglio, A.; Cattaneo, C.I.; Favaretto, E. et al. Treatment adherence towards prescribed medications in bipolar-II acute depressed patients: Relationship with cyclothymic temperament and “therapeutic sensation seeking” in response towards subjective intolerance to pain. J. Affect. Disord. 2013, 151, 596–604.
40. Calabrese, J.R.; Guelfi, J.D.; Perdrizet-Chevallier, C.; Agomelatine Bipolar Study Group. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord. 2007, 9, 628–635.
41. Fornaro, M.; McCarthy, M.J.; de Berardis, D.; de Pasquale, C.; Tabaton, M.; Martino, M.; Colicchio, S.; Cattaneo, C.I.; D’Angelo, E.; Fornaro, P. Adjunctive agomelatine therapy in the treatment of acute bipolar II depression: A preliminary open label study. Neuropsychiatr. Dis. Treat. 2013, 9, 243–251.
42. Kurlansik, S.L.; Ibay, A.D. Seasonal affective disorder. Am. Fam. Phys. 2012, 86, 1037–1041.
43. Levitan, R.D. The chronobiology and neurobiology of winter seasonal affective disorder. Dialogues Clin. Neurosci. 2007, 9, 315–324.
44. Lewy, A.J.; Sack, R.L.; Singer, C.M.; White, D.M.; Hoban, T.M. Winter depression and the phase-shift hypothesis for bright lightߣs therapeutic effects: History, theory, and experimental evidence. J. Biol. Rhythym. 1988, 3, 121–134.
45. Pjrek, E.; Winkler, D.; Konstantinidis, A.; Willeit, M.; Praschak-Rieder, N.; Kasper, S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007, 190, 575–579.
46. Pandi-Perumal, S.R.; Srinivasan, V.; Maestroni, G.J.M.; Cardinali, D.P.; Poeggeler B.; Hardeland, R. Melatonin: nature’s most versatile biological signal? FEBS J. 2006, 273, 2813–2838.
47. Gruca, P.; Przegalinski, E.; Mrowiec, S.; Lason, M.; Papp, M. Evidence for antidepressant and anxiolytic-like activities of melatonin and agomelatine in animal models. Eur. Neuropsychopharmacol. 2004, 14, S230.
48. De Berardis, D.; Acciavatti, T.; di Iorio, G.; Corbo, M.; Serroni, N.; Campanella, D.; di Emidio, F.; Piersanti, M.; Cavuto, M.; Martinotti, G. et al. The melatonergic system: Effects on sleep and implications for the treatment of psychiatric disorders. ChronoPhysiol. Ther. 2011, 1, 59–67.
49. Millan, M.J.; Brocco, M.; Gobert, A.; Dekeyne, A. Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: Role of 5-HT2C receptor blockade. Psychopharmacology 2005, 177, 448–458.
50. Millan, M.J.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V.; Rivet, J.M.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther. 2003, 306, 954–964.
51. Li, X.; Borjigin, J.; Snyder, S.H. Molecular rhythms in the pineal gland. Curr. Opin. Neurobiol. 1998, 8, 648–651.
52. Naguib, M.; Samarkandi, A.H. The comparative dose-response effects of melatonin and midazolam for premedication of adult patients: A double-blinded, placebo-controlled study. Anesth. Analg. 2000, 91, 473–479.
53. Karakaş, A.; Coşkun, H.; Kaya, A.; Kücük, A.; Gündüz, B. The effects of the intraamygdalar melatonin injections on the anxiety like behavior and the spatial memory performance in male Wistar rats. Behav. Brain Res. 2011, 222, 141–150.
54. Cheng, X.P.; Sun, H.; Ye, Z.Y.; Zhou, J.N. Melatonin modulates the GABAergic response in cultured rat hippocampal neurons. J. Pharmacol. Sci. 2012, 119, 177–185.
55. Stein, D.J.; Picarel-Blanchot, F.; Kennedy, S.H. Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. Hum. Psychopharmacol. 2013, 28, 151–159.
56. Stein, D.J.; Ahokas, A.A.; de Bodinat, C. Efficacy of agomelatine in generalized anxiety disorder: A randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol. 2008, 28, 561–566.
57. Fornaro, M. Agomelatine in the treatment of panic disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35, 286–287.
58. Fornaro, M. Switching from serotonin reuptake inhibitors to agomelatine in patients with refractory obsessive-compulsive disorder: A 3 month follow-up case series. Ann. Gen. Psychiatry 2011, 10, 5.
59. De Berardis, D.; Serroni, N.; Campanella, D.; Olivieri, L.; Moschetta, F.S.; Conti, C.M.; Conti, P.; di Giannantonio, M. A case of obsessive-compulsive disorder successfully treated with agomelatine monotherapy. J. Clin. Psychopharmacol. 2012, 32, 289–290.
60. De Berardis, D.; Conti, C.M.; Marini, S.; Ferri, F.; Iasevoli, F.; Valchera, A.; Fornaro, M.; Cavuto, M.; Srinivasan, V.; Perna, G. et al. Is there a role for agomelatine in the treatment of anxiety disorders? A review of published data. Int. J. Immunopathol. Pharmacol. 2013, 26, 299–304.
61. Da Rocha, F.F.; Correa, H. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD. Clin. Neuropharmacol. 2011, 34, 139–140.
62. Stein, D.J.; Ahokas, A.; Albarran, C.; Olivier, V.; Allgulander, C. Agomelatine prevents relapse in generalized anxiety disorder: A 6-month randomized, double-blind, placebo-controlled discontinuation study. J. Clin. Psychiatry 2012, 73, 1002–1008.
63. Stein, D.J.; Ahokas, A.; Márquez, M.S.; Höschl, C.; Oh, K.S.; Jarema, M.; Avedisova, A.S.; Albarran, C.; Olivier, V. Agomelatine in generalized anxiety disorder: An active comparator and placebo-controlled study. J. Clin. Psychiatry 2014, 75, 362–368.
64. Crippa, J.A.; Hallak, J.E.; Zuardi, A.W.; Chagas, M.H.; Quevedo, J.; Nardi A.E. Agomelatine in the treatment of social anxiety disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34, 1357–1358.
65. De Berardis, D.; Serroni, N.; Marini, S.; Moschetta, F.S.; Martinotti, G.; di Giannantonio, M. Agomelatine for the treatment of posttraumatic stress disorder: A case report. Ann. Clin. Psychiatry 2012, 24, 241–242.
66. Morera-Fumero, A.L.; Abreu-Gonzalez, P. Role of melatonin in schizophrenia. Int. J. Mol. Sci. 2013, 14, 9037–9050.
67. Monti, J.M.; BaHammam, A.S.; Pandi-Perumal, S.R.; Bromundt, V.; Spence, D.W.; Cardinali, D.P.; Brown, G.M. Sleep and circadian rhythm dysregulation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 43, 209–216.
68. Afonso, P.; Brissos, S.; Figueira, M.L.; Paiva, T. Discrepant nocturnal melatonin levels in monozygotic twins discordant for schizophrenia and its impact on sleep. Schizophr. Res. 2010, 120, 227–228.
69. Park, H.J.; Park, J.K.; Kim, S.K.; Cho, A.R.; Kim, J.W.; Yim, S.V.; Chung, J.H. Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J. Mol. Neurosci. 2011, 45, 304–308.
70. Morera-Fumero, A.L.; Abreu-Gonzalez, P. Diazepam discontinuation through agomelatine in schizophrenia with insomnia and depression. J. Clin. Psychopharmacol. 2010, 30, 739–741.
71. Martinotti, G.; di Iorio, G.; Marini, S.; Ricci, V.; de Berardis, D.; di Giannantonio, M. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: A review. J. Biol. Regul. Homeost. Agents 2012, 26, 347–356.
72. Bruno, A.; Zoccali, R.A.; Abenavoli, E.; Pandolfo, G.; Scimeca, G.; Spina, E.; Muscatello, M.R. Augmentation of clozapine with agomelatine in partial-responder schizophrenia: A 16-week, open-label, uncontrolled pilot study. J. Clin. Psychopharmacol. 2014, 34, 491–494.
73. De Berardis, D.; Valchera, A.; Fornaro, M.; Serroni, N.; Marini, S.; Moschetta, F.S.; Martinotti, G.; di Giannantonio, M. Agomelatine reversal of escitalopram-induced apathy: A case report. Psychiatry Clin. Neurosci. 2013, 67, 190–191.
74. Grosshans, M.; Mutschler, J.; Kiefer, F. Treatment of severe sleep disorder related to alcohol-dependence with high-dose agomelatine—A case report. Psychiatr. Danub. 2013, 25, 416–418.
75. Brower, K.J. Insomnia, alcoholism and relapse. Sleep Med. Rev. 2003, 7, 523–539.
76. Grosshans, M.; Mutschler, J.; Luderer, M.; Mann, K.; Kiefer, F. Agomelatine is effective in reducing insomnia in abstinent alcohol-dependent patients. Clin. Neuropharmacol. 2014, 37, 6–8.
77. Giamberardino, M.A.; Affaitati, G.; Fabrizio, A.; Costantini, R. Myofascial pain syndromes and their evaluation. Best Pract. Res. Clin. Rheumatol. 2011, 25, 185–198.
78. Maletic, V.; Raison, C.L. Neurobiology of depression, fibromyalgia and neuropathic pain. Front. Biosci. 2009, 14, 5291–5338.
79. Pernambuco, A.P.; Schetino, L.P.; Viana, R.S.; Carvalho, L.S.; D’Ávila Reis, D. The involvement of melatonin in the clinical status of patients with fibromyalgia syndrome. Clin. Exp. Rheumatol. 2014, in press.
80. Senel, K.; Baygutalp, F.; Baykal, T.; Erdal, A.; Ugur, M. Melatonin levels in premenopausal women with fibromyalgia syndrome. Rheumatol. Int. 2013, 33, 1609–1610.
81. Srinivasan, V.; Lauterbach, E.C.; Ho, K.Y.; Acuña-Castroviejo, D.; Zakaria, R.; Brzezinski, A. Melatonin in antinociception: Its therapeutic applications. Curr. Neuropharmacol. 2012, 10, 167–178.
82. Hussain, S.A.; Al-Khalifa, I.I.; Jasim, N.A.; Gorial, F.I. Adjuvant use of melatonin for treatment of fibromyalgia. J. Pineal Res. 2011, 50, 267–271.
83. Medina Ortiz, O.; Rico, G.; Oliveros, L.; Sánchez-Mora, N. Agomelatine adjunctive therapy for fibromyalgia. Reumatol. Clin. 2013, 9, 328–329.
84. Calandre, E.P.; Slim, M.; Garcia-Leiva, J.M.; Rodriguez-Lopez, C.M.; Torres, P.; Rico-Villademoros, F. Agomelatine for the treatment of patients with fibromyalgia and depressive symptomatology: An uncontrolled, 12-week, pilot study. Pharmacopsychiatry 2014, 47, 67–72.
85. Bruno, A.; Micò, U.; Lorusso, S.; Cogliandro, N.; Pandolfo, G.; Caminiti, M.; Zoccali, R.A.; Muscatello, M.R. Agomelatine in the treatment of fibromyalgia: A 12-week, open-label, uncontrolled preliminary study. J. Clin. Psychopharmacol. 2013, 33, 507–511.
86. Singh, M.; Jadhav, H.R. Melatonin: Functions and ligands. Drug Discov. Today 2014, 19, 1410–1418.
87. Tabeeva, G.R. Chronobiology of migraine. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2010, 110, 104–112.
88. Ong, J.C.; Park, M. Chronic headaches and insomnia: Working toward a biobehavioral model. Cephalalgia 2012, 32, 1059–1070.
89. Wilhelmsen, M.; Amirian, I.; Reiter, R.J.; Rosenberg, J.; Gögenur, I. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies. J. Pineal Res. 2011, 51, 270–277.
90. Peres, M.F.; Zukerman, E.; da Cunha Tanuri, F.; Moreira, F.R.; Cipolla-Neto, J. Melatonin, 3 mg, is effective for migraine prevention. Neurology 2004, 63, 757.
91. Fallah, R.; Shoroki, F.F.; Ferdosian, F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. Curr. Drug Saf. 2014, doi:10.2174/1574886309666140605114614.
92. Alstadhaug, K.B.; Odeh, F.; Salvesen, R.; Bekkelund, S.I. Prophylaxis of migraine with melatonin: A randomized controlled trial. Neurology 2010, 75, 1527–1532.
93. Tabeeva, G.R.; Sergeev, A.V.; Gromova, S.A. Possibilities of preventive treatment of migraine with the MT1- and MT2 agonist and 5-HT2c receptor antagonist agomelatin (valdoxan). Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2011, 111, 32–36.
94. Guglielmo, R.; Martinotti, G.; di Giannantonio, M.; Janiri, L. A possible new option for migraine management: Agomelatine. Clin. Neuropharmacol. 2013, 36, 65–67.
95. Gahr, M.; Kratzer, W.; Fuchs, M.; Connemann, B.J. Safety and Tolerability of Agomelatine: Focus on Hepatotoxicity. Curr. Drug Metabol. 2014, doi:10.2174/1389200215666140926155041.
96. Goodwin, G.M.; Emsley, R.; Rembry, S.; Rouillon, F.; Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo controlled trial. J. Clin. Psychiatry 2009, 70, 1228–1137.
97. Servier Laboratories Ltd. Agomelatine (Valdoxan): Monitor liver function and do not use in people with high transaminase levels (>3X ULN) or ≥ 75 years. Available online: http://www.mhra.gov.uk/home/groups/pl-p/documents/drugsafetymessage/con333634.pdf (accessed on 14 October 2013).
98. Valdoxan: Summary of Product Characteristic. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000915/WC500046227.pdf (accessed on 16 November 2014).
99. Stahl, S.M. Mechanism of action of agomelatine: A novel antidepressant exploiting synergy between monoaminergic and melatonergic properties. CNS Spectr. 2014, 19, 207–212.
100. Guardiola-Lemaitre, B.; de Bodinat, C.; Delagrange, P.; Millan, M.J.; Munoz, C.; Mocaër, E. Agomelatine: Mechanism of action and pharmacological profile in relation to antidepressant properties. Br. J. Pharmacol. 2014, 171, 3604–3619.